Background: Initially, unresectable colorectal liver metastases can be resected after response to chemotherapy. While cetuximab has been shown to increase response and resection rates, the survival outcome for this conversion strategy needs further evaluation.
introduction
In recent years, the emergence of multidisciplinary treatment approaches, the availability of new antineoplastic drugs and the characterization of molecular pathways have all contributed to an improvement in the therapy outcomes for patients with metastatic colorectal cancer. The finding that patients with initially unresectable liver metastases can become resectable after responding to chemotherapy and have a better long-term outcome than patients treated with chemotherapy alone [1] has led to the introduction of the concept of 'conversion chemotherapy' into clinical practice.
The epithelial growth factor receptor (EGFR) antibody cetuximab improves both the overall survival (OS) and response rate when combined with first-line chemotherapy in patients whose tumours are without K-RAS mutations [2, 3] . As a response to chemotherapy correlates with resection rate [4] , the improved efficacy shown by treatment regimens that included an EGFR antibody [5] made them of interest when investigating the concept of 'conversion chemotherapy' in patients with colorectal liver metastases.
In the CEtuximab in neoadjuvant treatment of unresectable colorectal LIver Metastases (CELIM) study, patients were randomised to receive either FOLFOX/cetuximab or FOLFIRI/cetuximab. We reported earlier a tumour response rate of 62% in all patients and 70% in patients with K-RAS codon 12/13/61 'wildtype tumours' [6] . The R0 resection rate for liver metastases was 34%, while the R0/1 resection and/or ablation rate was 46%. A surgical review of the computed tomography (CT) scans before and during treatment confirmed an improved resectability following treatment with chemotherapy plus cetuximab [6] .
In the current final analysis of this study, we report the longterm outcome for patients with initially unresectable colorectal liver metastases treated with chemotherapy plus cetuximab plus or minus secondary surgical resection of their metastases.
methods
This open, multicentre, randomised phase II trial studied either FOLFOX or FOLFIRI plus cetuximab in the treatment of patients with unresectable colorectal liver metastases. The primary end point was response rate. Secondary end points included resection rates, progression-free and OS, safety, and an assessment of predictive molecular markers of response and toxicity.
patient selection
Patients with 'unresectable' colorectal metastases confined to the liver were eligible for inclusion. 'Unresectability' was defined, according to the categories used in the EORTC 40983 trial investigating resectable patients [7] , as patients with metastases that were viewed as technically unresectable by local evaluation on the basis of inadequate future liver remnant or suboptimally resectable patients with ≥5 liver metastases. Patients fulfilling both of these inclusion criteria (≥5 metastases and technically unresectable) were grouped by the investigator to one of the two groups. Technical unresectability was defined as one of the following: infiltration of all liver veins, infiltration of the hepatic arteries or both portal vein branches. Enrolment was not limited to patients who were expected to become resectable after response to chemotherapy-patients with diffuse liver metastases were also eligible. In patients with synchronous liver metastases, the primary tumour had to be resected before study entry. Patients with a Karnofsky performance score of <80%, previous chemotherapy or EGFR-targeted therapy were excluded. Further details were described previously [6] .
procedures
Patients were randomised to receive either FOLFOX/cetuximab (group A), or FOLFIRI/cetuximab (group B). Planned treatment was for eight cycles after which tumours were assessed for resectability by a multidisciplinary team as described previously [6] . Resection was offered to those patients whose liver disease had become resectable. Patients whose disease was still classed as unresectable continued on treatment until disease progression and were assessed for resectability every four cycles.
Patient tumours were evaluated retrospectively for K-RAS and B-RAF mutations. Furthermore, a group of surgeons carried out a blinded review of the CT scans at baseline or after treatment [6] .
statistical analysis
OS and progression-free survival (PFS) were calculated from randomisation, and disease-free survival (DFS) from last resection within this protocol. The survival analysis was carried out in December 2012 using the Kaplan-Meier estimation and Cox regression analysis.
A multivariate analysis for OS, PFS and DFS was carried out with age (<65 versus ≥65 years), sex, number of metastases at baseline (<5 versus 5-10 versus >10), inclusion due to technically resectability or ≥5 metastases, resectability according to imaging review, treatment arm, K-RAS status, synchronous versus metachronous metastases, CEA (≤5, 5-50, >50 ng/ml) and white blood count (continuous variable). For OS and PFS, it was repeated with the post-treatment variables of resection (no resection versus resection and/or radiofrequency ablation), tumour response (confirmed partial response/complete response versus stable disease/progressive disease) and imaging review after treatment.
The sample size calculation, the definition of the primary end points and the detailed analysis of the surgical review were reported previously [6] .
ethics
All patients provided written informed consent. The study was approved by the health authorities and the local ethics committees.
results

patient population
Between December 2004 and March 2008, patients were randomised to receive either FOLFOX/cetuximab (group A, n = 56) or FOLFIRI/cetuximab (group B, n = 55) in 16 centres in Germany and 1 in Austria. Two patients in group A did not start study treatment due to withdrawal of consent or extrahepatic disease (retrospectively detected on pre-randomisation imaging). One patient in each group discontinued treatment before the first dose was fully completed. One patient in group B was not assessable for response due to their early death from pulmonary embolism ( Figure 1 ).
The patients' characteristics were reported earlier [6] . In summary, 70 patients had K-RAS codon 12/13/61 wild-type tumours, 29 patients had tumours with K-RAS mutations and 12 patients had tumours of unknown K-RAS mutational status. Three patients had tumours with a B-RAF mutation. Thirty patients (27%) had <5 liver metastases, 58 patients (52%) had 5-10 liver metastases and 19 patients >10 liver metastases (17%; unknown number in 4 patients). Fourteen patients had had previous liver surgery. Figure 2A ). The estimated 3-and 5-year OSs were 48.3% (95% CI 38.9% to 57.7%) and 27.5% (95% CI 18.7% to 36.3%), respectively, with an estimated PFS rate at 3 years of 5.7% (95% CI 1.4%-10.0%). There were no statistically significant differences regarding the outcome according to 'treatment group'. The median OS Figure 3A) . The 5-year survival rate for R0 resected patients was 46.2% (95% CI 29.5% to 62.9%). The median DFS 'for the 36 patients who had undergone R0 resection' was 9.9 (95% CI 5.8-14.0) months. Three patients (8%) remained disease free at 3 years. The number of metastases at baseline had a significant influence on the DFS time ( Figure 3B , P < 0.001).
Resections following response to chemotherapy, and tumour response itself had a major influence on the OS ( Figure 4A ). To explore the additional influence of liver resection in patients with a major response, a subgroup analysis for OS was carried out in patients who had achieved either a partial or complete response. Figure 4B demonstrates the prognostic influence of liver resection in this patient subgroup [ patients with R0 resection versus patients without resection: HR 0.42 (95% CI 0.21-0.86), P = 0.021].
We also analysed whether resectability determined during the retrospective imaging review was prognostic for survival.
Interestingly, resectability determined on the scans after chemotherapy but not at baseline was predictive for the OS in the univariate analysis (supplementary Figure S1A and 
discussion
Only a few years ago, the patients included in this study would have been regarded as incurable. Thus, in this context, the 5-year OS rate of ∼45% in R0 resected patients is perhaps the most important result of this trial, and confirms in a multicentre study the value of intensive 'conversion chemotherapy' together with liver surgery managed within a multidisciplinary environment. Both regimens in the present study achieved high response and resection rates. Of those patients not considered to be resectable before study treatment, 34% finally underwent R0 resection, and an additional 12% underwent R1 resection and/ or radiofrequency ablation [6] . There is probably-except for sufficient postoperatively remaining functional liver tissue-no generally accepted definition of unresectability. In particular, there is uncertainty about which patients should be regarded as 'oncologically unresectable' and in terms of treatment decision making about those patients who need technically demanding surgery but have an unfavourable prognosis. In the present study, we used the pragmatic definition of unresectability used for the EORTC 40983 study in patients with resectable liver metastases. Thus, our patients had either technically unresectable and/or ≥5 metastases. In situations where patients fulfilled both original articles Annals of Oncology inclusion criteria they were assigned by the investigator into one of the two groups. However, due to the lack of a clear definition of resectability/unresectability, it can never be excluded in the clinical practice setting, that patients regarded as unresectable in one centre might be considered to be resectable in another centre. The likelihood of a major discrepancy was 7% according to the blinded surgical review based on imaging information [6] . Interestingly, patients enrolled into the trial because they had ≥5 metastases (and not due to technically unresectable metastases) had a worse DFS according to the multivariate analysis emphasising that resectability should be defined by both technical and prognostic factors. Interestingly, according to the retrospective imaging review post-treatment resectability but not initial resectability was associated with a better OS, confirming the importance of conversion chemotherapy (supplementary Figure S1 , available at Annals of Oncology online). We are unable to conclude from the present trial to what extent cetuximab contributed to these favourable results, because all patients received EGFR antibody therapy. However, increased response rates and higher resection rates in patients with K-RAS wild-type tumours who received cetuximab plus FOLFIRI or FOLFOX versus chemotherapy alone were reported in both the CRYSTAL and OPUS studies which enrolled patients with both liver-limited and non-liver-limited metastatic colorectal cancer [2, 3] , and confirmed in a recently published randomised trial conducted in patients with unresectable, liverlimited, colorectal metastases [8] .
No statistically significant difference was detected between the combinations of FOLFOX/cetuximab and FOLFIRI/cetuximab in terms of efficacy. Although the statistical power is limited due to the sample size, this finding is interesting for the interpretation of the results of the COIN and NORDIC VII trials [9, 10] and suggests that the negative results of these two trials may not be attributable to combinations of cetuximab/ oxaliplatin but to other factors, such as the different fluoropyrimidine schedules. Recent findings have indicated that EGFR antibody therapy is ineffective in patients whose tumours carry K-RAS mutations beyond the most frequently tested exon 2 codon12/13 mutations and also in patients with N-ras-mutated tumours [11] . In this trial, patients had been tested for K-RAS mutations in codon 12, 13 (exon 2), codon 61 and B-RAF. The low frequency of further mutations is unlikely to change the study results.
Thus, long OS was achieved although only a few patients remained free of disease progression at 3 years. Although repeated resections of recurrent metastases might have cured additional patients [12] , surgery itself was not curative in the majority of patients. This finding is consistent with the findings of other studies of liver resection in initially unresectable patients [13, 14] .
Given the relative safety when used in experienced hands and the complete 'remission' achieved by liver surgery, such surgery, although often not curative, seems to make an important contribution to the overall continuum of care of the patients in our study and may reduce cell clones not sensitive to a given chemotherapy. Compared with the time to re-introduction (median 3-4 months) of chemotherapy following discontinuation of therapy in trials investigating stop-and-go strategies [15, 16] , the median DFS of 9.9 months for R0 resected patients in the present trial compares favourably, even if there was no durable cure, and represents a 'further line of palliative treatment'. This effect might be overestimated as all resected patients had a response to chemotherapy and therefore represent a better prognostic group. However, the beneficial effect of surgery can still be identified in the subset of patients who responded to chemotherapy ( Figure 4B ). These findings may provide a useful basis from which to discuss and manage patients' realistic expectations regarding the outcomes of a multidisciplinary team approach to their treatment. Recent results have shown that patients with metastatic colorectal cancer usually overestimate their probability of being cured [17] and their survival [18] , following chemotherapy. Early recurrence within the first 6 months after resection was observed in nearly one-third of the patients. A short disease-free interval was associated with a high number of liver metastases (>10) (Figure 3B ), synchronous metastases, and a high CEA level before treatment-factors well known to be associated with poor OS [19, 20] . Whether surgery improves OS in patients with a very high risk of recurrence and how this group can be best defined remains uncertain. Trials evaluating this question may be of value.
In conclusion, the CELIM study has demonstrated a favourable outcome for patients with liver-limited disease in a multicentre setting using a multidisciplinary treatment approach involving an effective systemic treatment followed by resection of their colorectal liver metastases, whenever possible. Whether the treatment can be improved by more intensive conversion therapy combinations, for example FOLFOXIRI/cetuximab [21] instead of FOLFIRI/ cetuximab or FOLFOXIRI/bevacizumab [22] instead of FOLFOXIRI is subject of current clinical trials (NCT01802645).
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